Health technology assessment

Insights and updates for more productive and successful HTA submissions

As healthcare treatments and interventions evolve, Health Technology Assessment bodies are continually adjusting their evidence requirements and negotiation frameworks. Our health economic, market access and regulatory teams can guide clients to understand the latest updates and prepare for successful access.

Ensuring scientific rigor in external control arms

Randomized controlled trials are the gold standard for determining the efficacy of a new therapy or evaluating its comparative effectiveness against the standard of care. Yet there are situations, such as in rare or orphan diseases, with breakthrough therapies, or in areas of high unmet medical need, when RCTs are either unfeasible or unethical.

Read the whitepaper

The impact of COVID-19 on HTA / reimbursement requirements

How will the changes brought about by the pandemic impact your existing pipeline of products? Will you need to adjust your existing HEOR evidence planning and timetables? Are there steps you can take to ensure that patients and providers will still have timely access to your pipeline of products?

Read the whitepaper

Seeking parallel consultation from regulators and HTAs in Europe

Understanding and meeting the evidence requirements of regulators and HTA bodies can be complex. Early engagement can help. Read the whitepaper for key factors to ensure that parallel consultation meetings are well prepared, productive and informative.

Read the whitepaper

Health technology assessment blogs and media contributions

Optimise Your Regulatory & HTA Submissions with a Comprehensive Health Economic & Epidemiologic Evidence Strategy

Gain insights to best practices for developing a comprehensive health economic and epidemiologic evidence strategy and evidence generation plan that is targeted to meet the needs of regulators and payers.

Watch webinar recording